The growing use of weight-loss drugs has led to a £1bn shift in what British customers buy in shops, with many products losing sales, according to the latest research.
Analysis from Worldpanel by Numerator found products including alcohol and crisps (both with sales down 15%) have been particularly badly hit, although its researchers stress that other foods have benefited.
Winners and losers in grocery sales
Portion-controlled options are doing well, while frozen ready meals have seen a 30% increase in volume, with hot chocolate and malted drinks a more unexpected beneficiary, up 22% in the amount spent and 16% in volume.
Chantel Kennaugh, head of public sector and nutrition at Worldpanel by Numerator, said: “Too often, the GLP-1 impact is framed as a story about value or volume decline, but there’s a much more interesting story sitting behind this.
“From a grocery perspective, this new audience is being more mindful about what and how they eat. The key for retailers is how to support them, without isolating them.
“This might be as simple as producing clear labels that highlight nutrients like high-protein or ensuring ranges are available in smaller portions sizes.”
Rise in weight-loss drug users
Researchers have described the change in buying behaviour as a “displacement” of spending and point out that it is driven by the rising number of households that now include weight-loss drug users. That has gone up from 6.3% in February to 8.5% in August, equating to 2.6 million adults.
This means there are as many weight-loss drug-takers in British homes as there are vegetarians and pescatarians combined. If compared with individual products, there are more people taking weight-loss medication than there are buying Corona beer or Kellogg’s Rice Krispies.
Nishita Pattni, senior consultant at Worldpanel by Numerator, said: “GLP-1 users are now found in as many British homes as some of Great Britain’s best-known food and drink brands, and growth is accelerating.
“In just six months, between February and August 2026, user numbers rose almost as much as they did in the whole of the previous year. For many people, a daily pill is far easier than an injection, and with the surge in male users, we only expect the appeal of these drugs to grow.”
Impact on the alcohol sector
Separate research from Lumina this week found the increasing use of GLP-1 drugs is having a particular impact on the alcohol sector. Findings included a loss of share for beer, while wine and cocktails are becoming more popular, low-and-no alcohol options are growing in relevance among this audience, and more-affluent consumers are trading volume for quality.